Easton Capital backs £3M Neupulse investment
Easton Group is pleased to announce its investment in Neupulse, alongside a consortium of private investors led by Eos Advisory. The £3M investment round will support the commercialisation of Neupulses’s pioneering wearable technology that helps manage tics in people with Tourette Syndrome as featured in the BAFTA award winning film, I Swear.
Neupulse is a neurotechnology company pioneering non-invasive neuromodulation solutions to improve quality of life for people living with neurological and mental health conditions. Combining neuroscience and user-centric design, Neupulse develops wearable technologies that deliver effective and drug free solutions.
The investment round will allow Neupulse to scale sales and support its path to market, product development, regulatory progress and early commercialisation, to ensure the company’s technology reaches individuals who need it most.